Biotechnology

Subcutaneously Administered PD-L1 Antibody ASC22 (Envafolimab) is Safe and Well Tolerated in Phase IIa HBV Study

HANGZHOU and SHAOXING, China, Dec. 4, 2020 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX:1672) announces today that Phase IIa data demonstrated that ASC22 (Envafolimab) is safe and well tolerated in chronic hepatitis B (CHB) patients and Phase IIb clinical trial has been initiated. ASC22 (Envafolima...

2020-12-04 08:00 3435

VolitionRx Limited Appoints Dr. Tom Butera DVM to Board of Directors

AUSTIN, Texas, Dec. 3, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases in both humans and animals, announced today the...

2020-12-03 21:30 9819

INOVIO Expands Global Manufacturing Consortium For Its COVID-19 Vaccine Candidate INO-4800 With Addition of Kaneka Eurogentec S.A.

Partnership with leading global plasmid manufacturer advances INOVIO's INO-4800 Kaneka Eurogentec to support production of INO-4800 PLYMOUTH MEETING, Pa., Dec. 3, 2020 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to ...

2020-12-03 21:00 5489

Antengene Submits NDAs for XPOVIO® (Selinexor) in Multiple APAC Markets for rrMM and rrDLBCL

SHANGHAI and HONG KONG, Dec. 3, 2020 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in class therapeutics in hematology and oncolo...

2020-12-03 20:00 5653

WuXi AppTec Recognized by Frost & Sullivan with 2020 Global Customer Value Leadership Award

SHANGHAI, Dec. 2, 2020 /PRNewswire/ -- WuXi AppTec, a leading global provider of R&D and manufacturing enabling services in the pharmaceutical, biotechnology and medical device industries, today announced that it has received the 2020 Global Customer Value Leadership Award from Frost & Sullivan, ...

2020-12-03 08:00 1716

WuXi AppTec Applauded by Frost & Sullivan for Its Unmatched Breadth of Expertise in Facilitating Early-stage Innovation and Clinical Research

The company accelerated clients' R&D and ensured agility by leveraging a global footprint, keen customer focus, and customized solutions. LONDON, Dec. 2, 2020 /PRNewswire/ -- Based on its recent analysis of the global contract research organization (CRO) market, Frost & Sullivan recognizes WuXi A...

2020-12-02 22:00 1480

BD to Invest $1.2 Billion in Pre-Fillable Syringe Manufacturing Capacity Over Next Four Years

FRANKLIN LAKES, N.J., Dec. 2, 2020 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced plans to invest approximately$1.2 billion over a 4-year period to expand and upgrade manufacturing capacity and technology for pre-fillab...

2020-12-02 20:00 3417

Tubulis Forms Strategic Partnership with WuXi Biologics and WuXi STA to Advance New Generation of Antibody-Drug Conjugates towards Clinical Evaluation

MUNICH and SHANGHAI, Dec. 2, 2020 /PRNewswire/ -- Tubulis, WuXi STA and WuXi Biologics today announced a strategic collaboration to manufacture and advance Tubulis' next generation antibody-drug conjugates (ADCs) towards IND-enabling studies. Tubulis has developed a dual platform approach to gene...

2020-12-02 19:00 1847

Ascentage Pharma Announces Clearances in China and the US for the Phase IIa Study of APG-115 Single Agent or in Combination with APG-2575 for the Treatment of Relapsed or Refractory T-cell Prolymphocytic Leukemia

SUZHOU, China and ROCKVILLE, Md., Dec. 2, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the Center for Drug Eval...

2020-12-02 08:09 2359

Volition Launches Nu.Q™ Vet Cancer Screening Test in the U.S.

AUSTIN, Texas, Dec. 1, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases in both humans and animals, has announced the l...

2020-12-01 21:45 9196

ViGeneron and WuXi Advanced Therapies Enter Strategic Manufacturing Partnership for Next-Generation Ophthalmic Gene Therapy

PHILADELPHIA and MUNICH, Dec. 1, 2020 /PRNewswire/ -- ViGeneron, a gene therapy company, and WuXi Advanced Therapies Inc. (WuXi ATU), a leading Contract, Testing, Development and Manufacturing Organization (CTDMO), today announced a strategic partnership to accelerate production for the clinical ...

2020-12-01 21:00 2512

Kaltech's Disinfectant Deodorizer Proved to Have Infectivity Suppression Effect against Novel Coronavirus (COVID-19) Floating in Fixed Space

OSAKA, Japan, Dec. 1, 2020 /PRNewswire/ -- Kaltech Co., Ltd., headquartered in Chuo-ku,Osaka, has announced that an experiment to test for 20 minutes the efficacy of a disinfectant deodorizer equipped with the company's proprietary photocatalytic technology against airborne novel coronavirus in a...

2020-12-01 14:05 2273

Taiwan-based Enterprises AP Biosciences and LuminX Novel Cancer Treatments

TAIPEI, Nov. 30, 2020 /PRNewswire/ -- In recent years, an increasing number of drugs have been granted breakthrough therapy designation inthe United States, encouraging more companies to propose novel cancer treatment solutions. Currently, there are two companies inTaiwan that are accelerating th...

2020-12-01 00:00 1226

RedHill Biopharma Expands U.S.-Based Manufacturing Capacity of Opaganib for COVID-19

RedHill adds two more manufacturing partners, both U.S.-based, for large-scale manufacturing of opaganib, in preparation for potential emergency use applications as early as Q1/2021 The new collaborations follow recently announced collaborations with European and Canadian manufacturers U.S. Pha...

2020-11-30 10:45 2869

Ascentage Pharma Enters into an Agreement with University of Michigan to obtain an exclusive license for a MDM2 Degrader using PROTAC Technology

SUZHOU, China and ROCKVILLE, Md., Nov. 30, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced it has entered into an ag...

2020-11-30 08:09 2232

Eluminex Biosciences, an Ophthalmology-Focused Biotechnology Company, Announces Closing of $50 Million Series A Financing

* Proceeds to fund development of novel and best-in-class therapeutics for eye diseases * Charles Semba, MD, joins the company to serve as Chief Medical Officer SHANGHAI, Nov. 27, 2020 /PRNewswire/ -- Eluminex Biosciences Limited (Eluminex), an ophthalmic biotechnology company committed to th...

2020-11-27 21:00 3829

Sedana Medical submits market approval application for the drug Sedaconda

STOCKHOLM, Nov. 27, 2020 /PRNewswire/ -- Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that the company has submitted an application for market approval for the drug candidate Sedaconda (isoflurane), formerly known as IsoConDa, for inhaled sedation in intensive care. The applica...

2020-11-27 20:35 2688

Nanoform launches technology for biologics and sets new near-term business target for 2021

HELSINKI, Nov. 27, 2020 /PRNewswire/ -- Nanoform Finland Plc ("Nanoform"), an innovative nanoparticle medicine enabling company, today announced a proprietary technology that can form biological nanoparticles as small as 50 nm and announced a new near-term business target for 2021 to deliver its ...

2020-11-27 14:04 1768

Haoma Medica Completes First-in-Human Trial for NaQuinate, a Novel Treatment in Development for Osteoporosis

LONDON, Nov. 27, 2020 /PRNewswire/ -- Haoma Medica announced today the completion of a first-in-human trial for NaQuinate, a naphthoquinone carboxylic acid, which is being developed as a novel orally administered therapeutic for osteoporosis.  The first-in-human trial initiated last year in heal...

2020-11-27 08:39 2221

Breakthrough in AML Treatment: GoldenBiotech Reports New Drug Trial of Antroquinonol -Outperforms Listing Drugs in Relapsed Acute Myeloid Leukemia

TAIPEI, Nov. 26, 2020 /PRNewswire/ -- Golden Biotechnology Corp.(GoldenBiotech, 4132.TWO), a leading Taiwanese biopharmaceutical company, announces that its new drug Antroquinonol (HOCENA®) outperforms the other listing drugs for the treatment of relapsed AML (acute myeloid leukemia) patients in ...

2020-11-26 21:35 2232
1 ... 227228229230231232233 ... 279